CSIMarket
 
Hologic Inc  (HOLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $75.9100 $0.57 0.757%
Day's High: $75.96 Week Perf: -0.55 %
Day's Low: $ 74.47 30 Day Perf: 3.77 %
Volume (M): 5,287 52 Wk High: $ 87.88
Volume (M$): $ 401,329 52 Wk Avg: $75.44
Open: $74.63 52 Wk Low: $64.02



 Market Capitalization (Millions $) 18,235
 Shares Outstanding (Millions) 240
 Employees 6,944
 Revenues (TTM) (Millions $) -3,082,076
 Net Income (TTM) (Millions $) 881
 Cash Flow (TTM) (Millions $) -509
 Capital Exp. (TTM) (Millions $) 99

Hologic Inc
Hologic Inc is a US-based medical technology company that specializes in diagnostic, surgical, and medical imaging equipment primarily for women's health. The company's headquarters are located in Marlborough, Massachusetts, and they have operations in over 50 countries globally.

The company was founded in 1985 and initially focused on developing osteoporosis diagnostic products. Since then, Hologic has expanded its scope and now offers a wide range of diagnostic and medical imaging equipment for cancer detection, gynecology, and skeletal health. They also provide surgical products and accessories for diagnostic imaging and breast biopsy procedures.

Hologic's imaging equipment is among the best in the industry, with the company providing the first-ever 3D mammography system, known as the Selenia Dimensions digital breast tomosynthesis (DBT) system, which was approved by the FDA in 2011. The system uses low-dose X-rays to provide multi-layered images of the breast, improving detection and decreasing the need for follow-up biopsies.

Hologic's advanced technologies also include the Panther Fusion system for molecular diagnostic testing, NovaSure for endometrial ablation to treat heavy menstrual bleeding, and MyoSure for removing uterine fibroids or polyps. Additionally, the company offers a range of products and services aimed at supporting women's health, including prenatal testing and infertility treatment.

Hologic's reputation in the medical industry is built on its commitment to quality and patient outcomes. They continue to invest in research and development, exploring innovative solutions that can improve women's health and transform the diagnostics and medical imaging industry as a whole.

In addition to their commitment to patient outcomes, the company also focuses on sustainability and corporate responsibility. They aim to reduce environmental impact, maintain ethical business practices, and promote diversity and inclusion in their workforce.

Overall, Hologic Inc is a leading medical technology company that offers cutting-edge diagnostic, surgical, and medical imaging equipment for women's health. They are dedicated to advancing medical technology, improving patient outcomes, and promoting corporate responsibility.


   Company Address: 250 Campus Drive, Marlborough, 1752 MA
   Company Phone Number: 263-2900   Stock Exchange / Ticker: NASDAQ HOLX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Hologic Inc

Hologic Inc. Shatters Expectations with Impressive Growth Despite Revenue Dip

Hologic Inc, a leading Medical Laboratories company, has managed to overcome challenges and deliver impressive growth in its recent fiscal interval closing December 30, 2023. Despite a decrease in revenue by -5.688% to $1.01 billion year on year, the company has achieved a significant increase in earnings per share (EPS) and profit per share.
During this period, Hologic Inc saw its profit per share soar by an impressive 37.33% to $1.03 per share. This marks a substantial improvement from the prior reporting season, with EPS more than doubling by 183.47% from $0.36 per share. The company has successfully turned around its revenue trend, which had previously been negative at $-3,085,100.00 million.

Hologic Inc

Unveiling Remarkable Growth: The Thriving Journey of Medical Laboratories Company up until September 30, 2023



Hologic Inc, a leading Medical Laboratories company, recently released its financial results for the fiscal period ending September 30, 2023. The results indicated a significant decline in income and net profits compared to the previous year. Additionally, the company's operating and net margins contracted, while inventories and accounts receivable witnessed fluctuations. This article aims to outline the facts and interpret the financial performance of Hologic Inc in context.
Financial Results:
1. Income and Earnings Per Share (EPS):
- Hologic Inc's income for the most recent fiscal period fell by -22.69% to $0.36 per share, contrasting with $0.47 per share reported in the previous financial reporting period.
- In the preceding financial reporting period, the company recorded an income per share of $-0.16.
- The decline in EPS is noteworthy, as it has decreased by -64.33% to $1.83 per share from $5.13 per share in the preceding fiscal period.

Hologic Inc

Hologic Inc's Surprising Financial Twist: $52.60 Million Tax Charge

As a stock market journalist, I have been closely examining the financial results of Hologic Inc for the May to July 01, 2023 fiscal span. The company appears to have slipped into a shortfall compared to the previous year, with a loss of $0.16 per share instead of a gain of $0.90 per share. Additionally, their income per share fell from $0.87 per share in the prior quarter. These figures indicate a decline in profitability for Hologic Inc.
The revenue for Hologic Inc also experienced a decrease, dropping by -1.825% to $984.40 million from $1.00 billion in the same quarter a year ago. Furthermore, the sequential revenue decreased by -4.101% from $1.03 billion. These declining revenues suggest a potential slowdown in the company's business activities.

Hologic Inc

Demanding three months for Hologic Inc in the fiscal second quarter of 2023

The stock market is always subject to changes and fluctuations based on the performance of individual companies. In the case of Hologic Inc, its recent performance in the second quarter of 2023 reveals an above-average return on equity of 21.6% compared to its industry peers and an overall ranking that has advanced in the quarter. This is promising news for investors, but caution must still be exercised.
Despite the net income growth of 16.6% from the first quarter of 2023, Hologic Inc's return on equity has diminished compared to the previous quarter. Additionally, the company's income per share plummeted by -55.38% in the second quarter of 2023, which is a significant decline from the year before. The company's revenue also fell by -30.222% compared to the previous year, and earnings for the quarter fell by -56.23%.






 

Hologic Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com